ClinicalTrials.gg
CompletedNCT03101670EQUATORUpdated Apr 23, 2018

A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis

A Phase 2 interventional study of filgotinib and Placebo Oral Tablet in Psoriatic Arthritis, sponsored by Galapagos NV. Completed at 25 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-23.

Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Arthritis, Psoriatic with a site in Ukraine — none open to participants now, 6 under way, 2 of them phase 3. Arthritis, Psoriatic · Ukraine.

Enrollment
17th of 20
131 · median 389
Started
2017
with 5 others
Phase 2
6 of 22
none open now
Registered
7th of 22
by date
Lead sponsor
3 of 22
Galapagos NV

Among the 22 studies in Arthritis, Psoriatic with a site in Ukraine, this one is the 17th largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2017, is one of 6 in phase 2, and was the 7th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

None of the 22 studies in Arthritis, Psoriatic with a site in Ukraine is open now. The open studies under Arthritis, Psoriatic, anywhere →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Arthritis, Psoriatic with a site in Ukraine as a file.
02

Study summary

This is a multicenter, Phase 2, double-blind, placebo-controlled study in subjects with moderately to severely active Psoriatic Arthritis (PsA) who have an inadequate response or are intolerant to conventional disease-modifying therapy. A total of approximately 124 subjects will be randomized to one of 2 treatment arms in a 1:1 ratio: oral filgotinib tablets q.d. or matching placebo tablets q.d. The Screening visit will occur within 28 days before study drug administration. At Day 1 (Baseline), eligible subjects will be randomized to treatment for a duration of 16 weeks. The study is concluded with a Follow-up period lasting until 4 weeks after the last dose. Consequently, each subject will stay in the study for a maximum of 24 weeks (from Screening visit to Follow-up visit).

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female subjects who are ≥18 years of age, on the day of signing .
  • Diagnosis of psoriatic arthritis meeting Classification Criteria for Psoriatic Arthritis (CASPAR)
  • Have active psoriatic arthritis defined as ≥5 swollen joints (from a 66 swollen joint count [SJC]) and ≥5 tender joints (from a 68 tender joint count [TJC]) at Screening and Baseline (measurable dactylitis of a digit counts as a single swollen joint and if tender, then also a single tender joint).
  • Have had a history of documented plaque psoriasis or currently active plaque psoriasis
  • If using cDMARD therapy, subjects must have been on it for 12 weeks prior to screening, with a stable dose (including stable route of administration) for at least 4 weeks prior to baseline.
  • If using non-drug therapies (including physical therapies), thse should be kept sable during screening
  • Male and female subjects of who engage in heterosexual intercourse must agree to use highly effective methods of as described in the protocol

Key Exclusion Criteria:

  • Use of JAK inhibitors, or approved, at any time, including filgotinib;
  • Prior use of more than one TNF inhibitor, at any time.
  • Use of oral at a dose >10 mg/day of prednisone or prednisone equivalent or at a dose that hasn't been stable for at least 4 weeks prior to Baseline;
  • Any therapy by intra-articular injections (e.g. corticosteroid, hyaluronate) within 4 weeks prior to screening;
  • Use of more than 1 NSAID or cyclooxygenase-2 (COX-2) inhibitor.
  • Have undergone surgical treatment for psoriatic arthritis including synovectomy and arthroplasty in more than 3 joints and/or within the last 12 weeks prior to screening
  • Presence of very poor functional status or unable to perform self-care.
  • Administration of a live or attenuated vaccine within 12 weeks prior to baseline
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    filgotinib

    Drug: filgotinib

  • Placebo comparator
    placebo

    Drug: Placebo Oral Tablet

Interventions

  • one filgotinib oral tablet q.d.

  • DrugPlacebo Oral Tablet

    one placebo oral tablet q.d.

06

What researchers measure

Primary outcomes

  1. Percentage of subjects who have reached ACR20 response as compared to placebo

    To assess the effect of filogotinib on PsA as assessed by ACR20 in PsA patients

    Time frame: Week 16

Secondary outcomes

  1. Assessment of minimal disease activity (MDA) in filgotinib treated subjects as compared to placebo

    To assess the effect of filogotinib on MDA in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  2. Percentage of subjects who have reached ACR50 response as compared to placebo

    To assess the effect of filogotinib on PsA as assessed by ACR50 in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  3. Percentage of subjects who have reached ACR70 response as compared to placebo

    To assess the effect of filogotinib on PsA as assessed by ACR70 in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  4. Percentage of subjects achieving DAS28(CRP) score as compared to placebo

    To assess the effect of filogotinib on PsA as assessed by DAS28 (CRP) in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  5. Percentage of subjects achieving SDAI response as compared to placebo

    To assess the effect of filogotinib on PsA as assessed by SDAI response in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  6. Percentage of subjects achieving CDAI response as compared to placebo

    To assess the effect of filgotinib on PsA as assessed by CDAI response in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  7. Percentage of subjects achieving EULAR response as compared to placebo

    To assess the effect of filogotinib on PsA as assessed by EULAR response in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  8. Assessment of psoriatic arthritis response criteria (PsARC) as compared to placebo

    To assess the effect of filogotinib on PsARC in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  9. Assessment of physician's and patient's global assessment of disease activity as compared to placebo

    To assess the effect of filogotinib on physician's and patient's global assessment of disease activity in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  10. Assessment of patient's global assessment of PsA pain intensity in filgotinib treated subjects as compared to placebo

    To assess the effect of filogotinib on on PsA pain intensity in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  11. Assessment of joints for tenderness (68) and swelling (66) in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on joint tenderness and swelling in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  12. Assessment of CRP in filgotinib treated subjects as compared to placebo

    To assess the effect of filogotinib on CRP in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  13. Psoriasis as assessed by PASI in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on PASI in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  14. Psoriasis as assessed by PASI50 in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on PASI50 in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  15. Psoriasis as assessed by PASI75 in filgotinib treated subjects as compared to placebo

    To assess the affect of filgotinib on PASI75 in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  16. Psoriasis as assessed by PASI90 in filgotinib treated subjects as compared to placebo

    To assess the affect of filgotinib on PASI90 in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  17. Psoriasis as assessed by PASI100 in filgotinib treated subjects as compared to placebo

    To assess the affect of filgotinib on PASI100 in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  18. Physician's and patient's global assessment of psoriasis in filgotinib treated subjects as compared to placebo

    To assess the affect of filgotinib on Physician's and patient's global assessment of psoriasis in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  19. Assessment of mNAPSI in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on mNAPSI in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  20. Assessment of pruritis NRS in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on NRS in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  21. Enthesitis as assessed by SPARCC enthesitis index in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on SPARCC enthesitis index in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  22. Dactilytis as assessed by LDI in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on Dactilytis in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  23. Physical function as assessed by HAQ-DI in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on physical function in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  24. FACIT-Fatigue scale in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on FACIT-Fatigue scale in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  25. Assessment of SF-36 in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on SF-36 in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  26. Assessment of Psoriatic Arthritis Impact of Disease Questionnaire (PsAID) in filgotinib treated subjects as compared to placebo

    To assess the effect of filgotinib on PsAID in PsA patients

    Time frame: At each visit from screening until the final follow up visit (week 20)

  27. Difference between the number of filgotinib treated subjects and placebo subjects in the number of adverse events

    To evaluation safety and tolerability of filgotinib in PsA patients

    Time frame: From screening until the final follow up visit (week 20)

  28. Difference between the number of filgotinib treated subjects and placebo subjects with abnormal clinical laboratory evaluations

    To evaluation safety and tolerability of filgotinib in PsA patients

    Time frame: From screening until the final follow up visit (week 20)

  29. Difference between the number of filgotinib treated subjects and placebo subjects with abnormal vital signs

    To evaluation safety and tolerability of filgotinib in PsA patients

    Time frame: From screening until the final follow up visit (week 20)

  30. Difference between the number of filgotinib treated subjects and placebo subjects with abnormal physical examination

    To evaluation safety and tolerability of filgotinib in PsA patients

    Time frame: From screening until the final follow up visit (week 20)

  31. Difference between the number of filgotinib treated subjects and placebo subjects with abnormal ECG

    To evaluation safety and tolerability of filgotinib in PsA patients

    Time frame: From screening until the final follow up visit (week 20)

  32. Difference between the number of filgotinib treated subjects and placebo subjects with abnormal radiographic assessment

    To evaluation safety and tolerability of filgotinib in PsA patients

    Time frame: From screening until the final follow up visit (week 20)

07

Study locations

25 sites
  • ULB Hopital Erasme, Service de Rheumatology
    Brussels, Belgium
  • UMHAT "Kaspela", EOOD
    Plovdiv, Bulgaria
  • MHAT - Ruse, AD
    Ruse, Bulgaria
  • UMHAT "SofiaMed", OOD, Block 1
    Sofia, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, Bulgaria
  • CCBR Czech, a.s
    Pardubice, Czechia
  • MEDICAL PLUS s.r.o.
    Uherské Hradiště, Czechia
  • Center for Clinical and Basic Research
    Tallinn, Estonia
  • North Estonia Medical Centre Foundation
    Tallinn, Estonia
  • OÜ Innomedica
    Tallinn, Estonia
  • Twoja Przychodnia-Centrum Medyczne Nowa Sol
    Nowa Sól, Poland
  • Ai Centrum Medyczne sp. z o.o. sp.k.
    Poznań, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej "Nasz Lekarz" Praktyka Grupowa Lekarzy Rodzinnych z, Przychodnia Specjalistyczna
    Toruń, Poland
  • Centrum Medyczne AMED, Warszawa Targowek
    Warsaw, Poland
  • Hospital Universitario de Fuenlabrada, Servicio de Reumatologia
    Fuenlabrada, Spain
  • Hospital Infanta Luisa, Servicio de Reumatologia
    Sevilla, Spain
  • CI of Healthcare Kharkiv CCH #8 Dept of Rheumatology Kharkiv MA of PGE of MOHU, Ch of Cardiology and Funct Diagnostics
    Kharkiv, Ukraine
  • CNI Consultative and Diagnostic Center of Pecherskyi District of Kyiv, Department of Therapy
    Kiev, Ukraine
  • SI NSС M.D. Strazhesko Institute of Cardiology of NAMSU, Unit of Non-coronary HD&Rh
    Kiev, Ukraine
  • CH of State Border Service of Ukraine (Military Base 2522) Dept of Therapy, D.Halytskyi Lviv NMU, Ch of Family Medicine & Dermatology, Venereology
    L'viv, Ukraine
  • M.V. Sklifosovskyi Poltava RCH Dept of Rheumatology HSEIU UMSA, Ch of Family Medicine and Therapy
    Poltava, Ukraine
  • CI of TRC
    Ternopil', Ukraine
  • M.I. Pyrogov VRCH Dept of Rheumatology M.I. Pyrogov VNMU, Ch of IM #1
    Vinnytsya, Ukraine
  • MCIC MC LLC Health Clinic, Unit of Cardiology and Rheumatology
    Vinnytsya, Ukraine
  • SRI of Invalid Rehabilitation (EST Complex) of Vinnytsia M.I.Pyrogov NMU MOHU, Un of Therapy and CRh Dept of Therapy
    Vinnytsya, Ukraine
08

References and documents

Publications

  • Orbai AM, Ogdie A, Gossec L, Tillett W, Leung YY, Gao J, Trivedi M, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Coates LC. Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Rheumatology (Oxford). 2020 Jul 1;59(7):1495-1504. doi: 10.1093/rheumatology/kez408. PubMed 31624837 ↗
  • Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, Abi-Saab W, Tasset C, Meuleners L, Harrison P, Besuyen R, Van der Aa A, Mozaffarian N, Greer JM, Kunder R, Van den Bosch F, Gladman DD. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Dec 1;392(10162):2367-2377. doi: 10.1016/S0140-6736(18)32483-8. Epub 2018 Oct 22. PubMed 30360969 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Mar 2018, 12 months.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2017
First posted
Apr 5, 2017
StartActual
Mar 9, 2017
Primary completionActual
Mar 12, 2018
CompletionActual
Mar 12, 2018
Last update
Apr 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03101670
Lead sponsor
Galapagos NV
Responsible party
Sponsor
First posted
Apr 5, 2017
Start date
Mar 9, 2017
Primary completion
Mar 12, 2018
Completion
Mar 12, 2018
Last update
Apr 23, 2018

Study contacts

Pille Harrison, MD, DPhil, MRCP (UK)
study director · Galapagos NV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion